Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on November 29, 2016. The filing reports a material corporate event regarding the pricing of a new debt offering.
Key Financial Metrics
The filing details the following capital market transaction:
- Debt Issuance: $110.0 million aggregate principal amount of 2.00% convertible senior notes due 2021.
- Over-Allotment Option: Initial purchasers were granted an option to purchase up to an additional $15.0 million aggregate principal amount of Notes.
- Interest Rate: 2.00%.
- Maturity Date: 2021.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing liquidity positions as this is a transaction-specific report rather than a periodic financial statement.
Material Changes
The primary material change is the execution of the convertible senior notes offering. The Notes and the Class A common stock issuable upon conversion are not registered under the Securities Act of 1933 and may not be offered or sold in the United States except pursuant to an exemption from registration requirements.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the pricing. The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell or a solicitation of an offer to buy the securities. No specific forward-looking guidance, risk factors, or contingencies beyond the standard securities law exemptions are detailed in the text of this specific filing.
Investor Verification Checklist
- Verify the final closing amount, including whether the $15.0 million over-allotment option was exercised.
- Review the full Press Release (Exhibit 99.1) for details on the use of proceeds.
- Examine the indenture agreement for specific conversion terms and covenants associated with the 2021 Notes.
- Confirm the impact of this new debt on the company's total leverage ratios in subsequent quarterly filings.